Jazz Pharmaceuticals plc Income (Loss) from Continuing Operations, Per Diluted Share
Jazz Pharmaceuticals plc (JAZZ) reported Income (Loss) from Continuing Operations, Per Diluted Share of $0.93 per share for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2015-02-24
- Jazz Pharmaceuticals plc income (loss) from continuing operations, per diluted share for the quarter ending 2013-09-30 was $1.23, a 119.64% increase year-over-year.
- Jazz Pharmaceuticals plc income (loss) from continuing operations, per diluted share for the quarter ending 2013-06-30 was $0.69, a 35.29% increase year-over-year.
- Jazz Pharmaceuticals plc income (loss) from continuing operations, per diluted share for the quarter ending 2013-03-31 was $0.71, a 36.54% increase year-over-year.
- Jazz Pharmaceuticals plc income (loss) from continuing operations, per diluted share for the quarter ending 2012-09-30 was $0.56, a 18.84% decline year-over-year.
- Jazz Pharmaceuticals plc income (loss) from continuing operations, per diluted share for fiscal 2014 was $0.93, a 73.50% decline from fiscal 2013.
- Jazz Pharmaceuticals plc income (loss) from continuing operations, per diluted share for fiscal 2013 was $3.51, a 19.12% decline from fiscal 2012.
- Jazz Pharmaceuticals plc income (loss) from continuing operations, per diluted share for fiscal 2012 was $4.34, a 62.55% increase from fiscal 2011.
- Jazz Pharmaceuticals plc income (loss) from continuing operations, per diluted share for fiscal 2011 was $2.67, a 221.69% increase from fiscal 2010.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.93 10-K · filed 2015-02-24 | |||
| 2013-12-31 | $3.51 10-K · filed 2015-02-24 | |||
| 2013-09-30 | $1.23 10-Q · filed 2013-11-05 | $2.62 10-Q · filed 2013-11-05 | ||
| 2013-06-30 | $0.69 10-Q · filed 2013-08-06 | $1.39 10-Q · filed 2013-08-06 | ||
| 2013-03-31 | $0.71 10-Q · filed 2013-05-07 | |||
| 2012-12-31 | $4.34 10-K · filed 2015-02-24 | |||
| 2012-09-30 | $0.56 10-Q · filed 2013-11-05 | $1.59 10-Q · filed 2013-11-05 | ||
| 2012-06-30 | $0.51 10-Q · filed 2013-08-06 | $1.03 10-Q · filed 2013-08-06 | ||
| 2012-03-31 | $0.52 10-Q · filed 2013-05-07 | |||
| 2011-12-31 | $2.67 10-K · filed 2014-02-25 | |||
| 2011-09-30 | $0.69 10-Q · filed 2012-11-09 | $1.88 10-Q · filed 2012-11-09 | ||
| 2010-12-31 | $0.83 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |